2024
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Pal S, Tran B, Haanen J, Hurwitz M, Sacher A, Tannir N, Budde L, Harrison S, Klobuch S, Patel S, Meza L, Dequeant M, Ma A, He Q, Williams L, Keegan A, Gurary E, Dar H, Karnik S, Guo C, Heath H, Yuen R, Morrow P, Agarwal N, Srour S. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. Cancer Discovery 2024, 14: of1-of14. PMID: 38583184, PMCID: PMC11215406, DOI: 10.1158/2159-8290.cd-24-0102.Peer-Reviewed Original ResearchClear cell renal cell carcinomaChimeric antigen receptorCAR-T cellsT-cell therapyCell renal cell carcinomaRenal cell carcinomaT cellsCell carcinomaSolid tumorsAllogeneic CAR-T cell therapyChimeric antigen receptor T cellsAdvanced clear cell renal cell carcinomaAllogeneic CAR-T cellsClinical trialsCAR-T cell productsCAR-T cell therapyTreatment of solid tumorsFirst-in-human clinical trialCAR-T constructsDose-limiting toxicityT cell productionNovel treatment optionsTreatment of clear cell renal cell carcinomaHematologic malignanciesAntigen receptorTargeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy
Alcantara M, Tang W, Wang D, Kaniowski D, Kang E, Dizman N, Chehrazi-Raffle A, Meza L, Zengin Z, Hall J, Hsu J, Egelston C, Moreira D, Horsager A, Pal S, Kortylewski M. Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy. Frontiers In Immunology 2024, 14: 1274781. PMID: 38259453, PMCID: PMC10800835, DOI: 10.3389/fimmu.2023.1274781.Peer-Reviewed Original ResearchImmune checkpoint blockadeDendritic cellsCancer patientsBladder cancerT cellsTumor-associated antigen-presenting cellsTherapeutic efficacyLesser extent IL-10T cell-based immunotherapyImmune checkpoint inhibitorsTumor immune evasionAntitumor immune responseCD8 T cellsRegulatory T cellsBladder cancer immunotherapyCell-based immunotherapyAntigen-presenting cellsSTAT3 activationRenal cancer patientsBladder cancer patientsImmune cell activityMyeloid immune cellsICB resistanceIpilimumab immunotherapyCheckpoint inhibitors
2023
Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles
Govindarajan A, Salgia N, Li H, Castro D, Mirzapoiazova T, Armstrong B, Zhao D, Mercier B, Dizman N, Chawla N, Zengin Z, Meza L, Tripathi N, Sayegh N, Chehrazi-Raffle A, Tripathi A, Pal S. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles. Frontiers In Immunology 2023, 14: 1182581. PMID: 37638025, PMCID: PMC10457014, DOI: 10.3389/fimmu.2023.1182581.Peer-Reviewed Original ResearchConceptsClear cell renal cell carcinomaPapillary renal cell carcinomaRenal cell carcinomaCell renal cell carcinomaCell carcinomaT cellsTumor microenvironmentPRCC cohortCcRCC cohortCcRCC patientsMain immune cell typesDistinct immunologic profileRCC histological subtypesMedian overall survivalProportion of CD4Baseline tumor tissueImmune cell populationsSubtypes of RCCImmune cell typesMass cytometry analysisCross-validate findingsSignificant differencesFFPE samplesMacrophage compositionTME compartments
2020
645 Preclinical development of a novel colon-targeted therapeutic for the treatment of immune checkpoint inhibitor (ICI)-colitis
Dizman N, Greenberg M, Newman A, Skupsky J, Hsu J, Zengin Z, Salgia N, Meza L, Chawla N, Salgia S, Malhotra J, Pal S. 645 Preclinical development of a novel colon-targeted therapeutic for the treatment of immune checkpoint inhibitor (ICI)-colitis. Journal For ImmunoTherapy Of Cancer 2020, 8: a682-a682. DOI: 10.1136/jitc-2020-sitc2020.0645.Peer-Reviewed Original ResearchICI therapySide effectsSystemic inflammationT cellsImmune checkpoint inhibitor therapyFrequent dose-limiting toxicityCandidate therapeuticsCenter Institutional Review BoardFavorable drug profileSigns of colitisCheckpoint inhibitor therapyImmune checkpoint inhibitorsDose-limiting toxicityMinimal systemic absorptionRegulatory T cellsAdoptive transfer modelAnti-inflammatory effectsSite of ulcerationT cell proliferationLife-threatening cancerRodent pharmacokinetic studyCancer-killing abilityInstitutional review boardActive colitisICI colitis